Last reviewed · How we verify
Atorvastatin and Omega-3 fatty acids — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Atorvastatin and Omega-3 fatty acids (Atorvastatin and Omega-3 fatty acids) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Atorvastatin and Omega-3 fatty acids TARGET | Atorvastatin and Omega-3 fatty acids | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Atorvastatin and Omega-3 fatty acids CI watch — RSS
- Atorvastatin and Omega-3 fatty acids CI watch — Atom
- Atorvastatin and Omega-3 fatty acids CI watch — JSON
- Atorvastatin and Omega-3 fatty acids alone — RSS
Cite this brief
Drug Landscape (2026). Atorvastatin and Omega-3 fatty acids — Competitive Intelligence Brief. https://druglandscape.com/ci/atorvastatin-and-omega-3-fatty-acids. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab